archive-com.com » COM » G » GLSV-VC.COM

Total: 39

Choose link from "Titles, links and description words view":

Or switch to "Titles and links view".
  • GLSV - Global Life Science Ventures
    companies primarily in Europe and the US After termination of the investment period the fund exited the remaining assets in 2015 and is in liquidation Currenty no new investments are being sought Profile Team Investment Practice Portfolio FAQ Download Area News Events Contact Us Home Sitemap Imprint Text size Featured issues 06 11 2013 Von GlycArt zur grossen Roche Hoffnung Extract from SECA eNewsletter no 388 more GLSV led the series A financing of GlycArt in November 2003 held a supervisory board position and also played an active role in initiating the trade sale process In 2005 Roche paid approximately CHF 235 million for the acquisition of the company The transaction was managed by ABN AMRO Portfolio company news 08 12 2015 Pieris Pharmaceuticals Announces First Cancer Immunotherapy Collaboration more 30 11 2015 Pieris Pharmaceuticals Achieves Payment Milestone in Sanofi Collaboration more 19 11 2015 Pieris Pharmaceuticals Collaborator Daiichi Sankyo Doses First Subject in a Phase 1 Clinical Study for Lead Partnered Anticalin Program more 30 09 2015 Positive Data Presented on Pieris Pharmaceuticals Inhaled Asthma Program at ERS and Company Strengthens Management Team more 15 09 2015 Pieris Pharmaceuticals Collaborator Presents Promising Preclinical Data on Tetraspecific Infectious Disease Anticalin

    Original URL path: http://www.glsv-vc.com/ (2016-04-25)
    Open archived version from archive


  • GLSV - Helping to build companies in the life science
    fund GLSV II started in 2001 and invested in 18 companies primarily in Europe and the US After termination of the investment period the fund exited the remaining assets in 2015 and is in liquidation Currenty no new investments are being sought Profile Experience History Clear Focus Key Strengths Track Record Team Investment Practice Portfolio FAQ Download Area News Events Contact Us Home Sitemap Imprint Text size Helping to build

    Original URL path: http://www.glsv-vc.com/profile/index.html (2016-04-25)
    Open archived version from archive

  • GLSV - Team and biographies
    and networks The group currently advises and manages funds totalling more than 200 million With offices in Germany and Switzerland GLSV acts as one team with a global perspective Profile Team Investment Practice Portfolio FAQ Download Area News Events Contact Us Home Sitemap Imprint Text size Team and biographies an industry born team investment strength through complementary skills science industry and finance GLSV has established a strong investment team and a network of advisors with many years of complementary experience in the life science industry The expertise of the team ranges from industrial experience in molecular biology immunology diagnostics and medical devices to marketing senior level strategic business development strategy consulting finance and administration This combination of skills gives companies access to a wealth of knowledge in science industry and finance that can be used to shape a successful commercial undertaking Dr Hans A Küpper Dr Peter H Reinisch Hanns Peter Wiese The in house expertise of the investment team will be fully exploited during the systematic evaluation of each potential investment In addition an external Expert Group has been established to expand this expertise on a case by case basis using their comprehensive understanding of the underlying scientific principles

    Original URL path: http://www.glsv-vc.com/team/index.html (2016-04-25)
    Open archived version from archive

  • GLSV - Investment Practice
    in 18 companies The second fund GLSV II started in 2001 and invested in 18 companies primarily in Europe and the US After termination of the investment period the fund exited the remaining assets in 2015 and is in liquidation Currenty no new investments are being sought Profile Team Investment Practice Lead Investor Syndicate Player Balanced Portfolio Added Value Steps to Investment Due Diligence Know how Network Ethical Values Portfolio

    Original URL path: http://www.glsv-vc.com/investment/index.html (2016-04-25)
    Open archived version from archive

  • GLSV - Portfolio Companies
    discovers and develops novel drugs based on CpG oligonucleotides CpG oligos or CpG molecules These drug candidates activate the innate and adaptive immune systems to fight diseases including cancer infectious diseases asthma and allergy Cyberkinetics Neurotechnology Systems Inc is active in the emerging field of neurotechnology Founded in 2001 the company is developing innovative devices for the treatment of nervous system dysfunction by combining recent advances in neuroscience computer science and engineering Cyberkinetics proprietary neurotechnology platform includes implantable devices that have the potential to control movement or communication via other external devices The company s brain computer interfaces have a broad potential not only for paralyzed or physically impaired humans but also as new devices to detect and treat neurological conditions such as stroke or epilepsy Website www cyberkineticsinc com Cytos Biotechnology AG is engaged in the discovery and development of a new class of biopharmaceutical products called Immunodrugs To stabilize prevent or reverse the disease process Immunodrugs instruct the patient s immune system to produce the desired antibodies or cytotoxic T cells to eliminate or block a disease associated protein Website www cytos com DeveloGen AG is a drug discovery company developing novel therapies for metabolic disorders based on extensive model organisms and stem cell expertise The company currently has two technology platforms focusing on metabolic phenotypic screens and harnessing key developmental control genes involved in stem cell differentiation and tissue regeneration Website www evotec com de develogen Exelixis Pharmaceuticals Inc is engaged in the identification and development of small molecule drugs for a range of diseases Through several unique model systems the company discovers and validates high quality novel targets for several major human diseases and is a leader in the discovery of potential new drug therapies for cancer and other proliferative diseases Website www exelixis com acquired by MChE in June 2014 Fibrex Medical Inc aims to become a leader in the development and commercialization of pharmaceuticals targeting fundamental mechanisms of inflammation based tissue injury FIBREX Medical has identified several synthetic peptides with novel mechanisms of action as lead compounds The most advanced development product FX06 aimed at the prevention of reperfusion injury after treatment for myocardial infarction will enter clinical studies soon GLYCART Biotechnology AG uses its proprietary GlycoMAb glycosylation engineering technology to boost the natural mechanism of action of therapeutic antibodies for target cell ablation The company develops its own GlycoMAb based portfolio of therapeutic antibodies targeting cancer and autoimmune diseases and offers to selected pharma and biotech companies improve their antibody based drug candidates with the GlycoMAb technology Website www roche ch schlieren html Horizon Pharma is the combined company formed by merger of Nitec Pharma with Horizon Therapeutics in April 2010 The company is developing and commercializing innovative medicines to target unmet therapeutic needs in arthritis pain and inflammatory diseases Website www horizonpharma com Intercell AG is a biotechnology company focused on the development of vaccines against infectious diseases and cancer Founded in 1998 the company is developing novel therapeutic and preventative vaccines

    Original URL path: http://www.glsv-vc.com/portfolio/index.html (2016-04-25)
    Open archived version from archive

  • GLSV - Frequently asked questions
    investment focus Who are the investors of GLSV What are your investment criteria and how do you value a company Do you also invest in late stage companies Which location should I contact How long does the investment process take How much on average do you invest in a company Do you support follow on financing What is your investment focus GLSV invests exclusively in the life sciences The geographic focus is on Europe including the United Kingdom Switzerland and home markets in German speaking countries as well as the United States of America Predominantly investments have and will continue to be made in early stage innovative companies Selected investments may also be made in later stages including buy outs Who are the investors of GLSV Investors in GLSV II include leading European banks insurance companies fund of funds and family offices What are your investment criteria and how do you value a company GLSV identifies and focuses on investment proposals with high potential After a preliminary review and selection of business plans which is followed by first personal presentations a typical due diligence process will include an assessment of the scientific or technological concept the unique selling proposition the international competitiveness intellectual property protection as well as the management team Depending on the stage of development of the company the analysis may also cover past and current operating performance management controls and reporting systems The due diligence is concluded by the preparation and finalisation of the legal documents Do you also invest in late stage companies In certain cases GLSV may decide to invest in later stage companies including buy outs which fulfil its investment criteria Which location should I contact If your company is domiciled in one of the countries in which GLSV maintains an office you are

    Original URL path: http://www.glsv-vc.com/faq/index.html (2016-04-25)
    Open archived version from archive

  • GLSV - Global Life Science Ventures
    Roche GlycArt AG Mitarbeiterzeitung myRoche Ausgabe 2011 2 Attraktives Chancen und Risikoprofil Was Venture Capital Investoren an Spin offs reizt VentureCapital Magazin Start up 2010 Hanns Peter Wiese Partner In der Frühphase fehlen solvente Investoren Going Public Biotechnologie 2009 Oktober 2009 Dr Holger Reithinger Partner Hanns Peter Wiese Partner VCs Dessert Stock Market Biotech Finances August 2009 Hanns Peter Wiese Partner Menschen Macher Teil 20 der Serie Köpfe der deutschsprachigen Private Equity Szene Venture Capital Magazin April 2008 Hanns Peter Wiese Europe s biotech maintains momentum Science Business October 2007 Biotech Startups suchen nach Geldquellen BÖRSE online October 2007 Dr Hans A Küpper Partner und Hanns Peter Wiese Partner Die transatlantische Connection Going Public Biotechnologie September 2007 Hanns Peter Wiese Partner Venture Capital steht wieder auf der Tagesordnung Transkript Nr 8 9 2007 Interview mit Dr Hans A Küpper Dr Holger Reithinger und Hanns Peter Wiese Glauben Sie noch an die deutsche Biotechnologie FINANCE September 2007 Hanns Peter Wiese Dr Hans Küpper und Dr Holger N Reithinger Nous avons observé des injections ciblées et messurées de capital Biotech Finances September 2007 Hanns Peter Wiese Partner Investment in European Biotech Outlook and Trends Dr Peter Reinisch s presentation at the 2006 Biotech in Europe Investor Forum featuring the results of the GLSV Biotech Investment Barometer Herausforderung Finanzierung Biotech Firmen in Europa Hanns Peter Wiese Going Public September 2006 The impact of biotechnology on modern healthcare and drug development Peter Reinisch partner of Global Life Science Ventures argues that biotechnology will play a decisive role in the development of the healthcare sector Privateequityonline July 2006 After the Hype The Horizons for Biotech Hanns Peter Wiese at Global Life Science Ventures scans the future in his examination of likely funding scenarious for 2006 ebr Bio Finance and Management spring 2006 Early Late Companies

    Original URL path: http://www.glsv-vc.com/download/index.html (2016-04-25)
    Open archived version from archive

  • GLSV - News
    Appoints Former Celgene and Sanofi Executive Jean Pierre Bizzari M D to its Board of Directors more 07 04 2015 Nabriva Therapeutics announces financing of up to 120 million to advance clinical development of new class of antibiotic more 30 03 2015 Pieris Pharmaceuticals and The University of Melbourne Receive Research Grant to Advance Immunological Diseases Program more 04 03 2015 Pieris to Present at Two Upcoming Conferences BIO Europe Spring 2015 the 27th Annual ROTH Conference more 04 03 2015 Agendia s BluePrint Molecular Subtyping Assay Highlighted at the 32nd Annual Miami Breast Cancer Conference more 10 02 2015 Agendia Receives New FDA Clearance for MammaPrint FFPE Breast Cancer Test more 29 01 2015 Nabriva Therapeutics strengthens Board and Management Team more 18 12 2014 Pieris Pharmaceuticals Inc Goes Public Raises 12 2 Million more 11 12 2014 Pieris Initiates Phase I Clinical Trial for Anticalin to Treat Anemia more 08 12 2014 Pieris Achieves GLP Tox Milestone Payment in Daiichi Sankyo Collaboration to Develop Anticalin Therapeutics more 04 12 2014 Agendia s MammaPrint and BluePrint Tests to be highlighted at San Antonio Breast Cancer Symposium more 01 12 2014 Pieris Achieves Second Preclinical Milestone Payment in Sanofi Collaboration more 12 11 2014 Pieris Appoints Michael Richman as Supervisory Board Member more 09 10 2014 Agendia Breast Cancer Test for Molecular Subtyping Improves Match of Therapy to Patient Study Finds more 08 10 2014 Nabriva Therapeutics announces qualified infectious disease product and fast track status granted by the US FDA for lefamulin more 02 10 2014 Agendia Board of Directors Appoints Jan Egberts M D as CEO more 15 09 2014 Agendia Test for Molecular Subtyping of Breast Cancer Is a Better Guide to Pre Surgical Treatment Study Finds more 08 09 2014 Nabriva Therapeutics presented data on lead pleuromutilin antibiotic lefamulin BC 3781 at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy in Washington DC more 03 09 2014 Nabriva Therapeutics Appoints Dr Colin Broom As Chief Executive Officer more 02 09 2014 Agendia Announces Study Showing Molecular Subtyping Can Improve Breast Cancer Treatment more 04 08 2014 Roche to acquire Santaris Pharma to expand discovery and development of RNA targeting medicines more 31 07 2014 Agendia Co Founder and CSO Develops Method to Identify Women Who Will Benefit from Tamoxifen Therapy for Breast Cancer more 16 07 2014 Agendia and CBLPath Announce Agreement to Assist Physicians in Diagnostic Assessment of Breast Cancer more 23 06 2014 Pieris Achieves Milestone Payment in Daiichi Sankyo Collaboration to Develop Anticalin Therapeutics more 10 06 2014 Value of Breast Cancer Molecular Subtyping Documented by Independent Study Comparing Genomic Tests at ASCO 2014 Meeting more 09 06 2014 African American Women More Likely to Be Diagnosed with Higher Risk Breast Cancer more 12 05 2014 Nabriva Therapeutics presents extended spectrum pleuromutilin antibiotics at the 24th European Congress of Clinical Microbiology and Infectious Diseases Barcelona more 07 05 2014 Molecular Subtyping with Agendia Tests Can Provide Better Guidance for Breast Cancer Treatment

    Original URL path: http://www.glsv-vc.com/news/index.html (2016-04-25)
    Open archived version from archive



  •